Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment
- PMID: 9734550
- DOI: 10.1176/ajp.155.9.1247
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment
Abstract
Objective: The purpose of this study was to determine prospectively the optimal length of therapy in a long-term, placebo-controlled continuation study of patients who responded to acute fluoxetine treatment for major depression (defined by DSM-III-R).
Method: The study was conducted at five outpatient psychiatric clinics in the United States. Patients who met criteria for remission after 12 or 14 weeks of open-label acute fluoxetine therapy, 20 mg/day (N=395 of 839 patients), were randomly assigned to one of four arms of a double-blind treatment study (50 weeks of placebo, 14 weeks of fluoxetine and then 36 weeks of placebo, 38 weeks of fluoxetine and then 12 weeks of placebo, or 50 weeks of fluoxetine). Relapse rate was the primary outcome measure. Both Kaplan-Meier estimates and observed relapse rates were assessed in three fixed 12-week intervals after double-blind transfers from fluoxetine to placebo at the start of the double-blind period and after 14 and 38 weeks of continued fluoxetine treatment.
Results: Relapse rates (Kaplan-Meier estimates) were lower among the patients who continued to take fluoxetine compared with those transferred to placebo in both the first interval, after 24 total weeks of treatment (fluoxetine, 26.4%; placebo, 48.6%), and the second interval, after 38 total weeks of treatment (fluoxetine, 9.0%; placebo, 23.2%). In the third interval, after 62 total weeks of treatment, rates were not significantly different between the groups (fluoxetine, 10.7%; placebo, 16.2%).
Conclusions: Patients treated with fluoxetine for 12 weeks whose depressive symptoms remit should continue treatment with fluoxetine for at least an additional 26 weeks to minimize the risk of relapse.
Comment in
-
Length of therapy for depression treatment.Am J Psychiatry. 1999 Nov;156(11):1839-40. doi: 10.1176/ajp.156.11.1839. Am J Psychiatry. 1999. PMID: 10553763 Clinical Trial. No abstract available.
Similar articles
-
Efficacy in long-term treatment of depression.J Clin Psychiatry. 1996;57 Suppl 2:24-30. J Clin Psychiatry. 1996. PMID: 8626360 Review.
-
The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.J Clin Psychiatry. 2000 Nov;61(11):851-7. doi: 10.4088/jcp.v61n1107. J Clin Psychiatry. 2000. PMID: 11105738 Clinical Trial.
-
Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial.Am J Psychiatry. 1997 Jan;154(1):37-43. doi: 10.1176/ajp.154.1.37. Am J Psychiatry. 1997. PMID: 8988956 Clinical Trial.
-
A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.Am J Psychiatry. 2002 Jan;159(1):96-102. doi: 10.1176/appi.ajp.159.1.96. Am J Psychiatry. 2002. PMID: 11772696 Clinical Trial.
-
Fluoxetine once every third day in the treatment of major depressive disorder.Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):307-12. doi: 10.1007/s00406-003-0445-2. Eur Arch Psychiatry Clin Neurosci. 2003. PMID: 14714120 Clinical Trial.
Cited by
-
Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.Psychopharmacol Bull. 2018 Jan 15;48(1):26-39. Psychopharmacol Bull. 2018. PMID: 29382958 Free PMC article.
-
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.J Clin Psychopharmacol. 2010 Jun;30(3):306-11. doi: 10.1097/JCP.0b013e3181da5300. J Clin Psychopharmacol. 2010. PMID: 20473068 Free PMC article. Clinical Trial.
-
Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.Behav Res Ther. 2013 Jul;51(7):392-8. doi: 10.1016/j.brat.2013.03.010. Epub 2013 Apr 12. Behav Res Ther. 2013. PMID: 23644038 Free PMC article. Clinical Trial.
-
Benzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression.J Clin Med. 2020 Jun 21;9(6):1938. doi: 10.3390/jcm9061938. J Clin Med. 2020. PMID: 32575832 Free PMC article.
-
Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis.Clin Psychol Rev. 2018 Aug;64:13-38. doi: 10.1016/j.cpr.2018.07.005. Epub 2018 Jul 29. Clin Psychol Rev. 2018. PMID: 30075313 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous